Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1200/jco.20.01605

License

CC-BY-NC-ND

Other Formats

PDF